Hemato Oncology Testing Market

Hemato Oncology Testing Market Size by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User & Region - Global Forecast to 2027

Report Code: MD 7180 Nov, 2022, by marketsandmarkets.com

The size of hemato oncology testing market in terms of revenue was estimated to be worth USD 2.9 billion in 2022 and is poised to reach USD 5.6 billion by 2027, growing at a CAGR of 14.2% from 2022 to 2027. The research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The growth in this market is attributed to the increasing number of the hematologic cancer patients as these patient require the regular monitoring and the diagnostic testing during the treatment. The clinical trials on hematologic cancers have increased in the last few years and the companies are requiring the hemato oncology testing product to preform the diagnostic assays which have certainly increased the collaboration between the companies, the increasing number of the diagnostic centers which provide diagnostic assay and services will drive the growth of the market.

Growth Opportunities Hemato Oncology Testing Market

Hemato Oncology Testing Market

Hemato Oncology Testing Market Growth Dynamics

Driver: Growing incidence of hematologic cancer

Over the years, the incidence of hematologic cancer has increased significantly. According to the Leukemia & Lymphoma Society, an estimated 1,519,907 people in the US are either living with, or are in remission from, leukemia, lymphoma, or myeloma. These patients require continuous monitoring during treatment. Also, monitoring of minimal residual disease (MRD) has become a routine clinical practice for acute lymphoblastic leukemia. Due to this, physicians prefer drugs combined with companion diagnostics to prevent adverse drug reactions in cancer patients and to reduce mortality rates. This is expected to fuel the demand for hemato-oncology testing products in the market.

The rising geriatric population across the globe is also a key factor supporting the increasing incidence of hematologic cancer, as this population segment is more prone to various chronic diseases. The rising geriatric population and the subsequent increase in the prevalence of hematologic cancers is expected to drive the growth of the hemato-oncology testing market.

Restraint: Unfavorable reimbursement scenario

The hemato-oncology testing market is currently witnessing rapid growth; however, reimbursement challenges in different regions could limit the market growth to a certain extent. Reimbursements for hemato-oncology testing vary widely across regions and countries. Currently, in most countries, regulatory procedures are not well-adapted to the hemato-oncology testing market. The current regulatory systems in these countries were developed for simple diagnostic tests and are not well-suited for novel biomarker-based diagnostics. Obtaining reimbursement is one of the major obstacles to the commercial adoption of hemato-oncology testing. The US government or private agencies do not cover analyte-specific reagents used to identify and quantify markers. As a result, diagnostic companies operating in these markets experience difficulties in seeking reimbursements for tests. The reimbursement levels for diagnostics set by the centers for Medicare and Medicaid Services (CMS) do not adequately reflect their actual cost or clinical value. Thus, the complex and highly diverse reimbursement scenario affects the efficient introduction of precision medicine based on targeted therapies. This often leads to uncertain reimbursement scenarios, consequently restricting the adoption of these tests.

Opportunity: Emerging markets

Emerging markets such as India, China, and Brazil offer significant growth opportunities for players operating in the hemato-oncology testing market owing to the rising geriatric population, growing incidence of hematologic cancers, rising health expenditure per capita, and improving healthcare infrastructure.

Challenge: Intellectual property rights protection issues

Several market players are facing challenges related to the intellectual property rights of their innovative diagnostic tests. Although drugs can be protected by patents, the patenting of biomarkers is still debatable in many countries (biomarker detection is fundamental in companion diagnostics). In cases where an intellectual property has been developed through collaboration between a drug developer and diagnostic developer, the drug developer is interested in controlling the ownership or exclusive licensing of any intellectual property related to the drug product; whereas, the diagnostic developer is interested in controlling the intellectual property related to the diagnostic and the general platform technology. Currently, there are no intellectual property laws related to products developed through such collaborations. In the case of co-ownership of the new product between these entities, issues may arise while licensing the product to third parties. For example, if the drug developer wants to license the diagnostic product to a competitor diagnostic company, the revenues of the diagnostic developer involved in the co-ownership will be affected. In order to avoid such complications, an exclusivity agreement can be signed, although this can also create other obstacles. For instance, after the co-development of a product by the drug developer and diagnostic developer, the diagnostic developer may fail to fulfill the market demand for the product. In such cases, the drug developer will be compelled to find another partner, which will not be allowed by the exclusivity agreement.

In 2021, services segment accounted for the largest share of the hemato oncology testing industry, by product

By products & services type, the global hemato oncology testing market is broadly segmented into services and assay kits. The services segment dominate the global hemato oncology testing market in 2021. The factor supporting the growth of the segment is the increase in the global burden of the disease diagnosis, advancement in diagnostic techniques and procedures and quality and affordability of the diagnostic testing.

In 2021, lymphoma dominated hemato oncology testing market

By cancer type, the hemato oncology testing market is divided into leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. Factor such as lower immunity, immune system deficiency, autoimmune diseases and family history and age can cause lymphoma.

In 2021, PCR dominated hemato oncology testing market

By technology, the global hemato oncology testing market is segmented into PCR, IHC, NGS, cytogenetics, and other technologies. In 2021, the PCR segment accounted for the largest share in the hemato oncology testing market. PCR is the most widely used technology in the diagnostic market which the easy use application, cost effective in nature, easy access to the kits and reagents.

In 2021, North America accounted for the largest share of the hemato oncology testing market

The global hemato oncology testing market is segmented into North America, Europe, Asia Pacific, and ROW. North America dominated hemato oncology testing market. The largest share can be attributed to the increasing number of the leukemia and lymphoma patients, growing awareness of the personalized medicine, increasing number of the owl age population and increasing collaboration for developing new assays kits.

Hemato Oncology Testing Market

The Hemato oncology testing market is dominated by players such as Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), and Illumina (US).

Scope of the Hemato Oncology Testing Industry

Report Metric

Details

Market Revenue Size in 2022

$2.9 billion

Projected Revenue Size by 2027

$5.6 billion

Industry Growth Rate

Poised to Grow at a CAGR of 14.2%

Market Driver

Growing incidence of hematologic cancer

Market Opportunity

Emerging markets

This research report categorizes the hemato oncology testing market to forecast revenue and analyze trends in each of the following submarkets

By Product & Service
  • Services
  • Assay Kits
By Cancer Type
  • Introduction
  • Leukemia
    • Acute myeloid leukemia
    • Acute lymphocytic leukemia
    • Other leukemia
  • lymphoma
    • Non-Hodgkin Lymphoma
    • Hodgkin Lymphoma
  • Other cancers
By Technology
  • Introduction
  • PCR
  • IHC
  • NGS
  • Cytogenetics
  • Others Technologies
by End User
  • Introduction
  • Clinical laboratories
  • Hospitals
  • Academic & Research Institutes
  • Other End Users
By Region
  • Introduction
  • North America
    • US
    • Canada
  • Europe
  • Asia Pacific
  • Rest of the World

Recent Developments of Hemato Oncology Testing Industry:

  • In 2022, F. Hoffmann-La Roche Ltd. (Switzerland) received FDA approval for the cobras EZH2 mutation test as a companion diagnostic for patients with follicular lymphoma
  • In 2020, F. Hoffmann-La Roche Ltd. (Switzerland) and Illumina Inc. (US) entered into a 15-year non-exclusive partnership with Illumina to broaden the adoption of NGS-based testing in oncology.
  • In 2021, QIAGEN N.V. (Germany) and Denovo Biopharma LLC (US) collaborated to develop a blood-based companion diagnostic (CDx) test for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.
  • Illumina, Inc. (US) acquired GRAIL (US) QIAGEN collaborated with DeNovo to develop a blood-based companion diagnostic (CDx) test for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.
  • In 2020, Thermo Fisher Scientific Inc. (US) and First Genetics JCS (Russia) came into a strategic partnership with First Genetics to focus on commercializing NGS-based diagnostics in Russia.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 20)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE 
          FIGURE 1 MARKETS COVERED
           1.3.1 REGIONAL SCOPE
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 MARKET STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 25)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
    2.2 SECONDARY DATA 
           2.2.1 SECONDARY SOURCES
           2.2.2 KEY DATA FROM SECONDARY SOURCES
    2.3 PRIMARY DATA 
          FIGURE 3 PRIMARY SOURCES
           2.3.1 KEY DATA FROM PRIMARY SOURCES
           2.3.2 KEY INDUSTRY INSIGHTS
    2.4 BREAKDOWN OF PRIMARY INTERVIEWS 
          FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
          FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.5 MARKET SIZE ESTIMATION 
                    FIGURE 6 HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH
           2.5.1 GROWTH FORECAST
                    FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.5.2 TOP-DOWN APPROACH
                    FIGURE 8 HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH
    2.6 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.7 RESEARCH ASSUMPTIONS 
    2.8 STUDY ASSUMPTIONS 
    2.9 INDICATORS AND OTHER ASSUMPTIONS 
    2.10 RISK ASSESSMENT 
           TABLE 1 RISK ASSESSMENT
    2.11 RESEARCH LIMITATIONS 
 
3 EXECUTIVE SUMMARY (Page No. - 37)
    FIGURE 10 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 41)
    4.1 HEMATO-ONCOLOGY TESTING MARKET OVERVIEW 
          FIGURE 15 GROWING INCIDENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2021) 
          FIGURE 16 HEMATO-ONCOLOGY TESTING SERVICES DOMINATED NORTH AMERICAN MARKET IN 2021
    4.3 GEOGRAPHICAL SNAPSHOT OF HEMATO-ONCOLOGY TESTING MARKET 
          FIGURE 17 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
 
5 MARKET OVERVIEW (Page No. - 43)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 18 HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing incidence of hematologic cancer
                                TABLE 1 GLOBAL HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020–2040
                                TABLE 2 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2030
                    5.2.1.2 Increasing collaborations between companies
                    5.2.1.3 Rising number of private diagnostic centers
                    5.2.1.4 Increasing conferences on personalized medicine
                                TABLE 3 HEMATO-ONCOLOGY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022–2023
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario
                                TABLE 4 REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS
                    5.2.2.2 Complex regulatory frameworks delaying approval of new molecular diagnostic tests
                    5.2.2.3 High capital investments and low cost-benefit ratio for biomarkers
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets
                                TABLE 5 CAPITAL HEALTH EXPENDITURE, BY COUNTRY, 2019
                                TABLE 6 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2020 VS. 2040
                    5.2.3.2 Drug diagnostics co-development
           5.2.4 CHALLENGES
                    5.2.4.1 Intellectual property rights protection issues
                    5.2.4.2 Shortage of trained professionals
 
6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (Page No. - 51)
    6.1 INTRODUCTION 
          TABLE 7 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
    6.2 SERVICES 
           6.2.1 RISING INCIDENCE OF HEMATOLOGIC CANCERS TO INCREASE DEMAND FOR HEMATO-ONCOLOGY SERVICES
                    TABLE 8 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 9 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
    6.3 ASSAY KITS 
           6.3.1 GROWING FOCUS ON DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE GROWTH
                    TABLE 10 HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
 
7 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE (Page No. - 55)
    7.1 INTRODUCTION 
          TABLE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
    7.2 LEUKEMIA 
          FIGURE 19 GLOBAL LEUKEMIA INCIDENCE, 2020
          TABLE 12 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
          TABLE 13 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
           7.2.1 ACUTE MYELOID LEUKEMIA
                    7.2.1.1 High incidence of AML in adults to drive growth
                                TABLE 14 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
           7.2.2 ACUTE LYMPHOCYTIC LEUKEMIA
                    7.2.2.1 High incidence of ALL in children to support growth
                                TABLE 15 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
           7.2.3 OTHER LEUKEMIAS
                    TABLE 16 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION)
    7.3 LYMPHOMA 
          TABLE 17 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
          TABLE 18 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
           7.3.1 NON-HODGKIN LYMPHOMA
                    7.3.1.1 Non-Hodgkin lymphoma to dominate market during forecast period
                                FIGURE 20 GLOBAL INCIDENCE OF NON-HODGKIN LYMPHOMA, 2020
                                TABLE 19 HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
           7.3.2 HODGKIN LYMPHOMA
                    7.3.2.1 APAC hemato-oncology testing market for Hodgkin lymphoma to grow at highest rate
                                FIGURE 21 GLOBAL INCIDENCE OF HODGKIN LYMPHOMA, 2020
                                TABLE 20 HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
    7.4 OTHER CANCERS 
          TABLE 21 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)
 
8 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY (Page No. - 64)
    8.1 INTRODUCTION 
          TABLE 22 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    8.2 PCR 
           8.2.1 PCR TECHNOLOGY TO DOMINATE HEMATO-ONCOLOGY TESTING MARKET
                    TABLE 23 HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION)
    8.3 IHC 
           8.3.1 ABILITY TO VISUALIZE TARGETED COMPONENTS IN SAMPLES TO BOOST ADOPTION
                       TABLE 24 HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION, 2020–2027 (USD MILLION)
    8.4 NGS 
           8.4.1 NGS SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
                       TABLE 25 HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION)
    8.5 CYTOGENETICS 
           8.5.1 HEAVY DEPENDENCE ON CYTOGENETIC ANALYSIS FOR DIAGNOSIS OF LEUKEMIA AND LYMPHOMA TO FUEL GROWTH
                       TABLE 26 HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION, 2020–2027 (USD MILLION)
    8.6 OTHER TECHNOLOGIES 
          TABLE 27 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
 
9 HEMATO-ONCOLOGY TESTING MARKET, BY END USER (Page No. - 70)
    9.1 INTRODUCTION 
          TABLE 28 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 CLINICAL LABORATORIES 
           9.2.1 PRESENCE OF ADVANCED INFRASTRUCTURE TO DRIVE MARKET
                    TABLE 29 HEMATO-ONCOLOGY TESTING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
    9.3 HOSPITALS 
           9.3.1 HIGH PATIENT FOOTFALL TO SUPPORT GROWTH
                    TABLE 30 HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION)
    9.4 ACADEMIC & RESEARCH INSTITUTES 
           9.4.1 GROWING MEDICAL RESEARCH AND DRUG DEVELOPMENT IN ACADEMIC & RESEARCH INSTITUTES TO FUEL GROWTH
                    TABLE 31 HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
    9.5 OTHER END USERS 
          TABLE 32 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
 
10 HEMATO-ONCOLOGY TESTING MARKET, BY REGION (Page No. - 75)
     10.1 INTRODUCTION 
             TABLE 33 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 22 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
             TABLE 34 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 35 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 36 NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 37 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
             TABLE 38 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 39 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 40 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 41 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.1 US
                        10.2.1.1 US to dominate North American hemato-oncology testing market during forecast period
                                      TABLE 42 US: LEUKEMIA AT A GLANCE
                                      TABLE 43 US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 44 US: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 45 US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 46 US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 47 US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 48 US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 49 US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Initiatives undertaken by healthcare authorities to support growth of market
                                      TABLE 50 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 51 CANADA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 52 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 53 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 54 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 55 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 56 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.3 EUROPE 
             10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET
                        TABLE 57 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 58 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
                        TABLE 59 EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 60 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 61 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 62 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 63 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
                        FIGURE 23 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT
                        TABLE 64 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 65 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 66 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
                        TABLE 67 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 68 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 69 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 70 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.5 REST OF THE WORLD 
             TABLE 71 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 72 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 73 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION)
             TABLE 74 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 75 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 76 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 77 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 95)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 
             TABLE 78 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATO-ONCOLOGY TESTING MARKET
     11.3 MARKET SHARE ANALYSIS, 2021 
             TABLE 79 HEMATO-ONCOLOGY TESTING MARKET: DEGREE OF COMPETITION
     11.4 COMPANY EVALUATION MATRIX 
             11.4.1 STARS
             11.4.2 EMERGING LEADERS
             11.4.3 PERVASIVE PLAYERS
             11.4.4 PARTICIPANTS
                        FIGURE 24 HEMATO-ONCOLOGY TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
     11.5 KEY STRATEGIES 
             11.5.1 PRODUCT LAUNCHES
                        TABLE 80 KEY PRODUCT LAUNCHES, JANUARY 2019–NOVEMBER 2022
             11.5.2 DEALS
                        TABLE 81 KEY DEALS, JANUARY 2019–AUGUST 2022
             11.5.3 OTHER DEVELOPMENTS
                        TABLE 82 OTHER KEY DEVELOPMENTS, JANUARY 2019–NOVEMBER 2022
 
12 COMPANY PROFILES (Page No. - 101)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 ABBOTT LABORATORIES
                        TABLE 83 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.2 F. HOFFMANN-LA ROCHE AG
                        TABLE 84 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 26 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
             12.1.3 QIAGEN N.V.
                        TABLE 85 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
             12.1.4 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 86 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             12.1.5 ILLUMINA, INC.
                        TABLE 87 ILLUMINA, INC.: BUSINESS OVERVIEW
                        FIGURE 29 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
             12.1.6 BIO-RAD LABORATORIES, INC.
                        TABLE 88 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 30 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             12.1.7 MOLECULARMD (A SUBSIDIARY OF ICON PLC)
                        TABLE 89 ICON PLC: BUSINESS OVERVIEW
                        FIGURE 31 ICON PLC: COMPANY SNAPSHOT (2021)
             12.1.8 ADAPTIVE BIOTECHNOLOGIES
                        TABLE 90 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
                        FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
             12.1.9 ARCHERDX, INC. (A SUBSIDIARY OF INVITAE CORPORATION)
                        TABLE 91 ARCHERDX, INC.: BUSINESS OVERVIEW
             12.1.10 ARUP LABORATORIES, INC.
                        TABLE 92 ARUP LABORATORIES, INC.: BUSINESS OVERVIEW
             12.1.11 ASURAGEN, INC.
                        TABLE 93 ASURAGEN, INC.: BUSINESS OVERVIEW
             12.1.12 INVIVOSCRIBE, INC.
                        TABLE 94 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
             12.1.13 AMOY DIAGNOSTICS CO., LTD.
                        TABLE 95 AMOY DIAGNOSTICS CO., LTD.: BUSINESS OVERVIEW
             12.1.14 ELITECHGROUP
                        TABLE 96 ELITECHGROUP: BUSINESS OVERVIEW
             12.1.15 VELA DIAGNOSTICS
                        TABLE 97 VELA DIAGNOSTICS: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 GENTRONIX LIMITED
             12.2.2 BIOIVT
             12.2.3 SAGA DIAGNOSTICS
             12.2.4 OLINK
             12.2.5 CANCER DIAGNOSTICS, INC.
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View 
(Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 138)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the hemato oncology testing market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

Extensive primary research was conducted after acquiring knowledge about the hemato oncology testing market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such clinical laboratories, hospitals, and academic & research institutes) and supply-side (such as product manufacturers, wholesalers, channel partners, and distributors). Approximately 42% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 58%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews. The following is a breakdown of the primary respondents:

Hemato Oncology Testing Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

All major product manufacturers offering various hemato oncology testing were identified at the global/regional level. Revenue mapping was done for the major players (who contribute at least 35-40% of the overall market share at the global level) and was extrapolated to arrive at the global market value of each type segment. The market value of hemato oncology testing market was also split into various segments and subsegments at the region and country-level based on:

  • Product and services mapping of various manufacturers for each type of hemato oncology testing market at the regional and country-level
  • Relative adoption pattern of each hemato oncology testing market among key cancer type segments at the regional and/or country-level
  • Relative adoption pattern of each hemato oncology testing market among key technology segments at the regional and/or country-level
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country-level
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level

Data Triangulation

After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the hemato oncology industry.

Hemato Oncology Testing Market

Report Objectives

  • To define, describe, and forecast the hemato oncology testing market based on the product, type, cancer type application, and region
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micro markets with respect to their growth trends, prospects, and contributions to the total market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the revenue of market segments with respect to five regions, namely, North America (US and Canada), Europe, Asia Pacific and ROW.
  • To strategically profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as collaborations, partnerships, acquisitions, expansions, and product launches in the hemato oncology testing market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global Hemato Oncology Testing Market report:

  • Company Information: Detailed analysis and profiling of additional market players (up to 5)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 7180
Published ON
Nov, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Hemato Oncology Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback